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Abstract
The synthesis of small organic molecules as probes for discovering new therapeutic agents has been
an important aspect of chemical-biology. Herein we report a reagent-based, diversity-oriented
synthetic (DOS) strategy to probe chemical and biological space via a “Click, Click, Cyclize”
protocol. In this DOS approach, three sulfonamide linchpins underwent cyclization protocols with a
variety of reagents to yield a collection of structurally diverse S-heterocycles. In silico analysis is
utilized to evaluate the diversity of the compound collection against chemical space (PC analysis),
shape space (PMI) and polar surface area (PSA) calculations.
Introduction
The synthesis of small organic molecules as probes for discovering new therapeutic agents has
been an important aspect of chemical-biology.1 Essential to this goal are two fundamental
features i) the production and access to libraries of skeletally diverse small molecules and ii)
biological evaluation and identification of new probes.2 Such small molecules have had a
dramatic effect in recent years providing invaluable insight into biological targets and the
development of therapeutic agents for curing disease.3 The generation of an open-data, high-
throughput screening environment of diverse small-molecule libraries has provided both a
number of new molecular probes as well as a novel insight into unmined chemical space.2 In
contrast to natural product-based targeted libraries premised on improving the biological
activity of the corresponding natural product, diversity-oriented-synthesis (DOS) derived
libraries aim to discover new molecules that exhibit biological effects beyond those associated
with the natural product. In this regard, DOS has emerged as a powerful strategy in the
generation of structurally complex and skeletally diverse small molecules.4
Synthetic protocols combined with rational design of small molecules based on structural
diversity, complexity and inherent physiochemical properties, has emerged as a rich area in
chemical biology.5 The ability to generate a collection of small molecules that combine not
only skeletal and peripheral complexity from a central building block, while remaining diverse
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in comparison to each other has been a challenging goal. Libraries synthesized utilizing a DOS
approach have been generated through a number of approaches. Seminal papers by Evans in
1988 and Schreiber 2000 reported the generation of substructural motifs as ligands for diverse
receptors.6 Recently, notable examples of DOS strategies have been reported by Spring, Park
and Shair.3,4 One of the more notable strategies employing both reagent-based7 and functional
group pairing attributes is the build/couple/pair (B/C/P) paradigm pioneered by Schreiber and
coworkers.8
Recently, a number of reports of sultams, the cyclic analogs of sulfonamides, have emerged
demonstrating a broad-spectrum bioactivity (Fig. 1), yet not “preordained bioactivity” as is the
case with targeted, medicinally active natural products. In particular, reports include anti-HIV
activity,9 antidepressant activity,10 inhibitors of RSV,11 selective tumour necrosis factor,12
and metalloproteinase.13 In addition to this potent biological profile, sultams and their
sulfonamide precursors possess a number of advantageous chemical properties. This potency,
when coupled with their unique chemical properties, elevates sultams as promising candidates
for drug discovery.
Despite these attributes, general strategies towards the synthesis of sultam libraries are lacking
in the literature.14 To address this challenge, we report a reagent-based DOS strategy termed
“Click, Click, Cyclize” en route to structurally diverse sultams from common sulfonamide
linchpins.15,16 In this strategy, skeletal diversity is incorporated into each small molecule via
a chosen orthogonal reagent used to cyclize each linchpin. As in functional-group pairing
approaches, this DOS strategy provides a pathway to a collection of diverse sultams.
Results and discussion
Linchpin synthesis via “Click, Click, Cyclize” protocol
Taking the aforementioned approach into hand, three unique sulfonamide linchpins 2, 9 and
15 were designed to yield a collection of sultams utilizing the aforementioned “Click, Click,
Cyclize” protocol.15 In this regard, linchpin 2 was synthesized via a “Click” mono-
sulfonylation of ethylenediamine with 2-bromobenzene sulfonamide 1, followed by a second
“Click” sulfonylation with tosychloride (TsCl) to generate the desired linchpin 2 in high yield
(Scheme 1).17 Utilizing a variety of reagents, five sultams and bis-sulfonamides (3–7) were
readily synthesised. Initial cyclization of linchpin 2 was achieved via a microwave-assisted,
Cu-catalyzed, intramolecular N-arylation yielding the corresponding sultam 3 in 70%.18
Alternatively, cyclization of linchpin 2 with either 1,2-dibromoethane or 1,3-dibromopropane
provided the desired piperazine 4 and diazepine 6 in good yield. In contrast, cyclization of
linchpin 2 with carbonyl diimidazole gave the corresponding imidazolidin-2-one 5 in 92%
yield. Finally, allylation followed by RCM yielded 7 in 88% yield, via a “click-cyclize” 2-step
protocol.
Building on these results, sulfonamide linchpin 9 was synthesized via sulfonylation of 2-
bromobenzylamine 8 with 2-chloroethanesulfonyl chloride followed by an aza-Michael
reaction with n-butylamine (Scheme 2).19 It was envisioned that cyclization with four
commercially available reagents would yield four skeletally diverse sultams (10–13).
Sultam 10 was synthesised via cyclization of linchpin 9 utilizing methyl 3-bromo-2-
(bromomethyl)propionate. Utilizing the same cyclization protocol as for the synthesis of 4 and
5, sultams 11 and 12 were synthesized via cyclization of linchpin 9 with 1,2-dibromoethane
or 1,3-dibromopropane, respectfully. Finally, sultam 13 was synthesized utilizing a
microwave-assisted, copper-catalyzed N-arylation protocol.
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Utilizing a previously developed Cu-catalyzed, N-arylation protocol, sulfonamide linchpin
15 was readily synthesized on scale from sulfonylchloride 14 (Scheme 3).18 The first
cyclization route, utilized a CDI cyclization protocol yielding sultam 16 in good yield. In an
attempt to synthesize sultam 18, linchpin 15 was treated with 3-bromo-2-(bromomethyl)
propionate in DMF at 60 °C. However, the desired product 18 was not isolated and instead
sulfonamide 17 was isolated in 78% yield. Finally, linchpin 15 readily underwent cyclization
with 1,2-dibromoethane to yield bicyclic sultam 19 in good yield.
To evaluate the diversity that is contributed by this collection of molecules and hence their
associated chemical descriptors, in silico algorithms were utilized to evaluate the S-
heterocycles reported. With each molecule possessing its own set of unique descriptors, every
small molecule has a discrete point in chemical space. Therefore, the more chemical space
probed by a collection of molecules, the greater the associated diversity. This metric of diversity
in chemical space can be represented by a principle component (PC) analysis (Fig. 2). In order
to gauge the chemical diversity of the sultams and sulfonamides (3–7, 10–13 and 16–19)
reported herein, we plotted them in a chemical space plot corresponding to a set of five BCUT
descriptors relative to 3770 FDA approved compounds as reported in ZINC database (Fig. 2).
20 This plot demonstrated that this collection of molecules both covered a significant area of
chemical space but also the compounds did not cluster together according to the corresponding
linchpin they were derived from.
Building on this analysis, sultams and sulfonamides (3–7, 10–13 and 16–19), were plotted
according to the normalized principal moment of inertia (PMI) formalism of Sauer and
Schwartz, in order to gauge the shape-based distribution (Fig. 3).21 The PMI plot is a rapid and
visual way to demonstrate diversity corresponding to the area of shape space covered by a
collection of molecules. This is a significant property for a collection of molecules to possess,
as broad biological activity has been correlated to shape space.21 Hence, screening collections
possessing a high degree of molecular shape diversity increases the chances of a broad range
of biological activity. Each molecule was aligned to principal inertial moment axes in SYBYL,
22 and the normalized PMI values were computed via a program developed in-house (available
upon request to the authors). With this plot in hand, Fig. 3 demonstrates a large coverage of
shape space for sultams and sulfonamides (3–7, 10–13 and 16–19). Of note is the coverage by
compounds 10–13 (red data points) derived from linchpin 8 further demonstrating the diversity
achieved utilizing a “Click, Click, Cyclize” approach.
In addition to diversity in both chemical and shape space, polar surface area of a small molecule
is a key feature in terms of diverse bioactive molecules involved in ligand-receptor binding.
Rigid scaffolds bearing diverse polar surface areas interact differently with various key
interactions such as hydrogen bonding, electrostatic and other non-covalent interactions. This
is further exemplified by reports that demonstrate the diverse biological activity associated
with small molecules with diverse polar surface areas resulting from different orientations of
heteroatoms.4a In this regard, polar surface area distribution of sultams 3, 4, 5 and 7 were
plotted (Fig. 4). Comparison among the four further demonstrates the degree of diversity
achieved from linchpin 2 utilizing a “Click, Click, Cyclize” protocol. Surface electrostatic
profiles were calculated by projecting the Gasteiger-Marsili charge distribution onto a
Connolly surface generated via the MOLCAD tool in SYBYL.22
Conclusions
In summary, we have utilized a “Click, Click, Cyclize” strategy to synthesize a collection of
skeletally diverse heterocycles in a DOS approach. Three distinct sub-sets of molecules were
prepared via the cyclization of sulfonamide linchpins with a variety of reagents. In silico
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analysis using a variety of metrics demonstrates the degree of diversity from this collection in
regards of chemical space, shape space and polar surface area.
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Biologically active sultams and sulfonamides.
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Three-dimensional chemical diversity plot of compounds 2–7 (green), 9–13 (red) and 14–19
(blue) relative to 3770 FDA approved compounds as reported in the ZINC database. The axes
reflect normalized projections of three H-sensitive three-dimensional BCUT metrics chosen
as having optimal variance levels within the MLSMR screening set, including the 600
projection of the Burden H-donor (horizontal axis), and the 500 (vertical axis) and 600 (out-
out-plane axis) projections of the Burden tab-polar projections, as computed via
DiverseSolutions.20
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Principal moment of inertia (PMI) plot of compounds 3–7 (green), 10–13 (red) and 16–19
(blue) as computed for energetically minimized conformers of the compounds using Gasteiger-
Marsili electrostatics.
Rolfe et al. Page 8














Surface electrostratic profiles of sultams and sulfonamides 3 (78.33), 4 (100.61), 5 (125.49)
and 7 (92.95). The compounds have been mutually aligned so that the conserved phenylsulfonyl
moiety is located in the upper left corner for each molecule. The surface corresponds to the
H2O-accessible Connolly surface, and the colouring reflects the Gasteiger-Marsili charge
distribution, such that electronegative areas are colored red, electro positive areas are blue.
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a) CuI, 1,10-phenanthroline, Cs2CO3, DMF, MW, 70%. b) (CH2Br)2, Cs2CO3, DMF, 60 °C,
90%. c) CDI, Et3N, DMF, 60 °C, 92%. d) CH2(CH2Br)2, Cs2CO3, DMF, 60 °C, 85%. e) i.
Allyl bromide, NaH, THF, RT, ii. Grubbs 2nd Generation, DCM, reflux, 88% (over steps).
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a) Cs2CO3, MeO2CCH(CH2Br)2, DMF, 64%. b) (CH2Br)2, Cs2CO3, DMF, 60 °C, 84%. c)
CH2(CH2Br)2, Cs2CO3, DMF, 60 °C, 76%. d) CuI, 1,10-Phenanthroline, K2CO3, DMF,
MW, 56%.
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a) CDI, Et3N, DMF, 60 °C, 96%. b) Cs2CO3, MeO2CCH(CH2Br)2, DMF, 78%. c)
(CH2Br)2, Cs2CO3, DMF, 60 °C, 87%.
Rolfe et al. Page 12
Org Biomol Chem. Author manuscript; available in PMC 2010 June 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
